Sequential Therapy vs Triplet Therapy for Patients With Newly Diagnosed AML Ineligible for Intensive Chemotherapy
At the 2024 Great Debates & Updates (GDU) in Hematologic Malignancies meeting in New York, Jessica Altman, MD, Northwestern University, Chicago, Illinois, argues in favor of using sequential therapy over triplet therapy for patients with newly diagnosed acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy.
Transcript:
Hi, good morning. My name is Jessica Altman. I direct the leukemia program at Northwestern University in Chicago I'm speaking to you from Great Debates and Updates in [Hematologic Malignancies in] New York City. It's our first Great Debates and Updates series of the year and it's been an outstanding meeting where we talk about exciting, and sometimes controversial, topics for the treatment of hematologic malignancies.
I have the pleasure of debating my dear colleague Kristen O'Dwyer on the role of triplet therapies for the treatment of adults with newly diagnosed acute myeloid leukemia, who are not candidates for intensive chemotherapy. I took the side of sequential therapy and not triplet therapy, and what I think we [concluded], both of us together, is that triplets are currently being studied for the treatment of adults who are not candidates for intensive chemotherapy, as ways are building upon our proofed regimen of hypomethylating agents and venetoclax.
But, due to [the] lack of substantial randomized and large data sets, those are not quite ready for primetime, that we're hopeful that those regimens will be available in the future for our patients. This is an area of exciting clinical research and something that's worthy of continuing to monitor and hopefully will be an option for our patients in the future.
Source:
Altman J. Debate- It Is the Age of Triplets for Treatment of Adults Who Are Ineligible for IC – NO. Presented at the 2024 Great Debates & Updates in Hematological Malignancies: April 5-6, 2024. New York City, NY.
© 2024 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.
